Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 12, 2008

Archemix and NascaCell Enlarges Focus of Aptamer-Based Partnership

  • Archemix and NascaCell Technologies expaned their original alliance, in which NascaCell obtained a sublicense to use Selex technology for aptamer-based target validation and drug screening applications. The new collaboration is focused on the use and development of aptamers for drug discovery applications.

    Aptamers are synthetically-derived oligonucleotides. Archemix believes that they have broad application to treat a variety of human diseases.

    Under the terms of the new agreement, NascaCell will receive nonexclusive rights to the use of aptamers for target validation, mode of action studies, drug discovery, and aptamer structure-based drug design. All future aptamer technology improvements will be cross-licensed between the companies. Archemix will also have the option of contracting NascaCell to generate aptamers for its own applications.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »